Cargando…
An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed to oncogenes mutations, activated defensive mechanisms, ATP-bind cassette transporters overexpression, cancer stem cel...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582727/ https://www.ncbi.nlm.nih.gov/pubmed/37860119 http://dx.doi.org/10.3389/fphar.2023.1274336 |
_version_ | 1785122396256075776 |
---|---|
author | Ye, Qingmei Zhou, Xin Ren, Han Han, Fangxuan Lin, Rong Li, Juan |
author_facet | Ye, Qingmei Zhou, Xin Ren, Han Han, Fangxuan Lin, Rong Li, Juan |
author_sort | Ye, Qingmei |
collection | PubMed |
description | Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed to oncogenes mutations, activated defensive mechanisms, ATP-bind cassette transporters overexpression, cancer stem cells, etc. Chinese traditional medicine toad venom has been used for centuries for different diseases, including resistant cancers. Bufalin is one of the bufadienolides in toad venom that has been extensively studied for its potential in refractory and drug-resistant cancer treatments in vitro and in vivo. In this work, we would like to critically review the progress made in the past decade (2013–2022) of bufalin in overcoming drug resistance in cancers. Generally, bufalin shows high potential in killing certain refractory and resistant cancer cells via multiple mechanisms. More importantly, bufalin can work as a chemo-sensitizer that enhances the sensitivity of certain conventional and targeted therapies at low concentrations. In addition, the development of bufalin derivatives was also briefly summarized and discussed. We also analyzed the obstacles and challenges and provided possible solutions for future perspectives. We hope that the collective information may help evoke more effort for more in-depth studies and evaluation of bufalin in both lab and possible clinical trials. |
format | Online Article Text |
id | pubmed-10582727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105827272023-10-19 An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives Ye, Qingmei Zhou, Xin Ren, Han Han, Fangxuan Lin, Rong Li, Juan Front Pharmacol Pharmacology Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed to oncogenes mutations, activated defensive mechanisms, ATP-bind cassette transporters overexpression, cancer stem cells, etc. Chinese traditional medicine toad venom has been used for centuries for different diseases, including resistant cancers. Bufalin is one of the bufadienolides in toad venom that has been extensively studied for its potential in refractory and drug-resistant cancer treatments in vitro and in vivo. In this work, we would like to critically review the progress made in the past decade (2013–2022) of bufalin in overcoming drug resistance in cancers. Generally, bufalin shows high potential in killing certain refractory and resistant cancer cells via multiple mechanisms. More importantly, bufalin can work as a chemo-sensitizer that enhances the sensitivity of certain conventional and targeted therapies at low concentrations. In addition, the development of bufalin derivatives was also briefly summarized and discussed. We also analyzed the obstacles and challenges and provided possible solutions for future perspectives. We hope that the collective information may help evoke more effort for more in-depth studies and evaluation of bufalin in both lab and possible clinical trials. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582727/ /pubmed/37860119 http://dx.doi.org/10.3389/fphar.2023.1274336 Text en Copyright © 2023 Ye, Zhou, Ren, Han, Lin and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ye, Qingmei Zhou, Xin Ren, Han Han, Fangxuan Lin, Rong Li, Juan An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
title | An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
title_full | An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
title_fullStr | An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
title_full_unstemmed | An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
title_short | An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
title_sort | overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582727/ https://www.ncbi.nlm.nih.gov/pubmed/37860119 http://dx.doi.org/10.3389/fphar.2023.1274336 |
work_keys_str_mv | AT yeqingmei anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT zhouxin anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT renhan anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT hanfangxuan anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT linrong anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT lijuan anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT yeqingmei overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT zhouxin overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT renhan overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT hanfangxuan overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT linrong overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives AT lijuan overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives |